Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years
KC Herold, S Gitelman, C Greenbaum, J Puck… - Clinical …, 2009 - Elsevier
Anti-CD3 mAbs may prolong β cell function up to 2 years in patients with new onset Type 1
diabetes (T1DM). A randomized open label trial of anti-CD3 mAb, Teplizumab, in T1DM was
stopped after 10 subjects because of increased adverse events than in a previous trial
related with higher dosing of drug. Teplizumab caused transient reduction in circulating T
cells, but the recovered cells were not new thymic emigrants because T cell receptor
excision circles were not increased. There was a trend for reduced loss of C-peptide over 2 …
diabetes (T1DM). A randomized open label trial of anti-CD3 mAb, Teplizumab, in T1DM was
stopped after 10 subjects because of increased adverse events than in a previous trial
related with higher dosing of drug. Teplizumab caused transient reduction in circulating T
cells, but the recovered cells were not new thymic emigrants because T cell receptor
excision circles were not increased. There was a trend for reduced loss of C-peptide over 2 …